TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the research and development of innovative therapeutic platforms targeting autoimmune, inflammatory, and age-related diseases. Its core mission centers on addressing the root biological mechanisms of these conditions, rather than merely alleviating symptoms. The company's flagship candidate, MYMD-1®, is a small molecule drug designed to regulate the immune response by inhibiting tumor necrosis factor-alpha (TNF-α), a cytokine that plays a pivotal role in chronic inflammation and autoimmune disorders. This agent is being investigated for a broad range of indications, including rheumatoid arthritis, inflammatory bowel disease, sarcopenia, and adverse effects linked to diabetes and obesity treatments. Additionally, TNF Pharmaceuticals is developing Supera-CBD, a novel synthetic derivative of cannabidiol intended for use in chronic pain, addiction, and epilepsy, aiming to build upon and refine current cannabinoid-based therapies. As a firm with a focused portfolio and strategic research partnerships—such as its alliance with the DADA2 Foundation for rare inflammatory disease research—TNF Pharmaceuticals occupies a significant niche within the biotechnology sector, contributing novel therapeutic approaches to some of today's most challenging and underserved medical conditions.